Thrivent Financial for Lutherans Invests $3.31 Million in Mirum Pharmaceuticals, Inc. $MIRM

Thrivent Financial for Lutherans purchased a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 41,857 shares of the company’s stock, valued at approximately $3,306,000.

A number of other large investors have also made changes to their positions in the business. MCF Advisors LLC increased its position in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of Mirum Pharmaceuticals by 34.0% during the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after purchasing an additional 243 shares in the last quarter. Arizona State Retirement System increased its position in shares of Mirum Pharmaceuticals by 2.6% during the third quarter. Arizona State Retirement System now owns 10,984 shares of the company’s stock worth $805,000 after purchasing an additional 275 shares in the last quarter. Comerica Bank increased its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares in the last quarter. Finally, Osaic Holdings Inc. increased its position in shares of Mirum Pharmaceuticals by 46.5% during the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares in the last quarter.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 7,287 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the sale, the chief financial officer directly owned 49,788 shares of the company’s stock, valued at approximately $4,579,500.24. This represents a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Peetz sold 40,985 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the completion of the sale, the chief executive officer directly owned 194,309 shares in the company, valued at approximately $17,872,541.82. The trade was a 17.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 76,806 shares of company stock valued at $7,064,616 in the last 90 days. 14.36% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM opened at $98.62 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. The stock’s fifty day moving average price is $96.20 and its 200 day moving average price is $88.41. Mirum Pharmaceuticals, Inc. has a 1 year low of $42.89 and a 1 year high of $114.99. The company has a market cap of $6.01 billion, a price-to-earnings ratio of -7.25 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. During the same period in the previous year, the company earned ($0.30) earnings per share. Mirum Pharmaceuticals’s revenue was up 43.3% on a year-over-year basis. As a group, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on MIRM shares. Wolfe Research started coverage on Mirum Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $145.00 target price on the stock. Leerink Partners cut their target price on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. Royal Bank Of Canada upped their target price on Mirum Pharmaceuticals from $128.00 to $142.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Morgan Stanley upped their target price on Mirum Pharmaceuticals from $130.00 to $140.00 and gave the company an “overweight” rating in a research report on Tuesday, May 5th. Finally, Stifel Nicolaus set a $136.00 target price on Mirum Pharmaceuticals in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average target price of $137.08.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.